Candida Germ Tube Protein IgG

Blood cultures miss about half of invasive candidiasis across its full spectrum. Deep Candida can be in tissue, in an abscess, or in an organ rather than in the sampled bloodstream. CAGTA looks for the serum or plasma IgG response your body makes against the germ-tube form of Candida.

Most people carry Candida harmlessly on skin and in the gut. The medical question is not whether Candida exists somewhere. It is whether it has crossed into normally sterile tissue or blood. This antibody is an adjunctive clue. It is not a stand-alone diagnosis.

What the Test Is Actually Measuring

Candida albicans can grow as a round yeast or as long threads called germ tubes and hyphae. The thread form helps Candida stick to surfaces and invade tissue. One well-studied surface protein on that form is Hwp1.

This is a blood draw. The lab tests serum or plasma for CAGTA, usually IgG antibodies to antigens on the Candida albicans germ-tube cell wall. Older assays used indirect immunofluorescence after absorbing out common anti-yeast antibodies. Newer automated assays use a machine-read antibody method. Both are trying to enrich the signal for invasive growth rather than ordinary colonization.

Invasive Candidiasis in High-Risk Patients

The evidence is in hospitalized, high-risk people: intensive care patients, people recovering from major abdominal surgery, and people with blood cancers on intensive chemotherapy. That is where this test belongs. Not in wellness screening.

Sources: Lain et al. 2007 measured a related Hwp1 serum IgG assay, not the exact commercial CAGTA test. Parra-Sanchez et al. 2017 studied VirClia CAGTA. Martinez-Jimenez et al. 2015 studied CAGTA paired with beta-D-glucan.

Do not read the best rows as the average. A 2019 meta-analysis of 7 CAGTA studies found moderate accuracy: roughly two thirds of invasive cases were detected and about three quarters of non-cases were called negative. Some cohorts did much better, especially C. albicans deep-seated disease. Some did worse. A positive result in the right clinical setting should move the workup forward. A negative result cannot rule the disease out by itself.

Telling Deep Infection From a Catheter Source

When Candida is already growing in blood culture, CAGTA can answer a narrower question: has the infection seeded a deep organ, or does it look catheter-related and limited to the line? In one 50-person candidemia study, about 7 in 10 deep-seated cases were CAGTA positive, compared with 1 in 21 non-deep-seated cases.

That changes the search. Deep disease calls for imaging, looking for abscesses or organ infection, and longer treatment. A catheter source may turn on removing the line and confirming the blood clears.

The Survival Finding, and Why It Looks Backwards

One result seems to say the wrong thing. In a 53-person ICU study, the CAGTA-positive group died less often than the negative group, and a positive test was the only independent factor tied to surviving the ICU. These exact mortality numbers come from a single small cohort and have not been widely replicated, so treat them as a signal, not a settled figure. Read at face value, that sounds as if the antibody is protective. That cannot be the whole story.

CAGTA is not a good-number, bad-number marker. It reflects two things at once: Candida may be invading, and your immune system is still able to make a measurable antibody response. The sickest or most immunosuppressed patients may test negative because they cannot mount that response. A positive result is a sign the body is fighting and the infection has become visible to the assay, not a sign the infection is safe.

How It Compares to Blood Cultures and Beta-D-Glucan

This antibody is best understood next to the two tests it usually runs with, because each is blind to something the others catch.

Sources: Clancy and Nguyen 2018 (Journal of Clinical Microbiology); IDSA 2016 candidiasis guideline; Peman et al. 2011 (BMC Infectious Diseases).

This test is sometimes paired with beta-D-glucan. In one candidemia study, CAGTA plus beta-D-glucan detected nearly all cases and had a high negative predictive value, so the combination was proposed for stopping unnecessary empirical antifungals when the clinical picture also fit. The evidence is mixed, though. Other ICU work, including a 2026 substudy of the randomized CandiSep trial and an earlier ICU cohort in which CAGTA added little discriminatory value, found that combining markers did not clearly outperform a single antigen test and that antibody assays were affected by colonization. No single result is enough to carry the decision.

Why This Is Not a Screening Test for Healthy People

The studies behind this marker were done in hospitalized, high-risk patients. They did not test apparently healthy adults, and they did not show that screening a well person changes outcomes. CAGTA assays are used in some European centers, but they are not widely used in North America and are not FDA-cleared as routine U.S. diagnostics. Even where the test is used, current guidelines give it only a marginal recommendation and stress that it be read alongside cultures, other biomarkers, and the clinical picture. It belongs in a suspected-invasive-candidiasis workup, not in a general wellness panel.

Low-risk testing creates a math problem. Invasive candidiasis is rare in healthy people, so even a fairly specific test can produce more confusion than clarity. A positive result without fever, hospitalization, surgery, chemotherapy, central lines, or another real risk factor should not be treated as proof of hidden infection.

Why Serial Testing Matters

Antibodies take time to build. CAGTA can be negative early, especially before the immune response has caught up. In one profoundly immunosuppressed leukemia patient with hepatosplenic candidiasis, the germ-tube antibody lagged a mixed-antigen Candida antibody test by 22 days.

In high-risk studies, serial CAGTA mattered more than a lone draw. In older hematology data, titers fell or disappeared in survivors; in ICU data, rising titers among treated patients were linked to lower mortality, though treatment was not assigned based on CAGTA. During an active risk window, serial results tell you more than one draw. The trend is a clue for a clinician, not an answer by itself.

When Results Can Be Misleading

• A weakened immune response: chemotherapy, blood cancers, neutropenia, transplant drugs, or other immunosuppression can blunt antibody production and produce a false negative during real invasive infection.
• Antifungal treatment history: treatment can change the chance of active infection and the species involved. It does not make the test useless, but it makes a single result harder to read.
• Testing too early: drawn before the antibody response has developed, the result can read negative when infection is present.
• Species and assay differences: CAGTA is built around Candida albicans germ-tube antigens. It has still detected several non-albicans species in some studies, but performance for them is less predictable, and manual CAGTA, automated VirClia, and Hwp1 ELISA are related but not identical tests.
• Colonization: heavy Candida colonization can influence antibody assays, which is one reason a positive result is read alongside cultures and the clinical picture rather than alone.
• Low-risk testing: in a healthy person with no real invasive-candidiasis risk, a lone positive is more likely to confuse the workup than diagnose hidden disease.

What to Do With an Unexpected Result

A positive result in someone with risk factors or symptoms is not a wait-and-see finding. It should trigger an invasive Candida workup: beta-D-glucan, repeat blood cultures, species identification if anything grows, and imaging to look for a deep focus. If invasive candidiasis is suspected, treatment is usually an IV echinocandin while cultures, imaging, and source control are sorted out.

The combinations matter. A positive result in a healthy person with no risk factors should be repeated and read cautiously. A negative result when suspicion is high should not reassure you on its own; pair it with beta-D-glucan and repeat, because the antibody may simply not have appeared yet.